Want to join the conversation?
$BIIB 2Q15 Call: Expects to pay approx. $850MM in CVR payments in 2015. Anticipates CapEx of approx. $650-700MM, an increase over 2014. Expects Phase 3 for TYSABRI in SPMS in 2015. Phase 3 for SMN-Rx expected late 2016 or early 2017. Clinical results for Phase 2 of BAN2401 and E2609 expected in 2016.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!